These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models. Guimaraes LC; Costa PAC; Scalzo Júnior SRA; Ferreira HAS; Braga ACS; de Oliveira LC; Figueiredo MM; Shepherd S; Hamilton A; Queiroz-Junior CM; da Silva WN; da Silva NJA; Rodrigues Alves MT; Santos AK; de Faria KKS; Marim FM; Fukumasu H; Birbrair A; Teixeira-Carvalho A; de Aguiar RS; Mitchell MJ; Teixeira MM; Vasconcelos Costa V; Frezard F; Guimaraes PPG Nat Commun; 2024 Jan; 15(1):590. PubMed ID: 38238326 [TBL] [Abstract][Full Text] [Related]
12. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Hoffmann MAG; Yang Z; Huey-Tubman KE; Cohen AA; Gnanapragasam PNP; Nakatomi LM; Storm KN; Moon WJ; Lin PJC; West AP; Bjorkman PJ Cell; 2023 May; 186(11):2380-2391.e9. PubMed ID: 37146611 [TBL] [Abstract][Full Text] [Related]
13. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Ye Z; Bonam SR; McKay LGA; Plante JA; Walker J; Zhao Y; Huang C; Chen J; Xu C; Li Y; Liu L; Harmon J; Gao S; Song D; Zhang Z; Plante KS; Griffiths A; Chen J; Hu H; Xu Q Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2311752120. PubMed ID: 38134199 [TBL] [Abstract][Full Text] [Related]
14. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977 [TBL] [Abstract][Full Text] [Related]
15. Modulating Lipid Nanoparticles with Histidinamide-Conjugated Cholesterol for Improved Intracellular Delivery of mRNA. Jung O; Jung HY; Thuy LT; Choi M; Kim S; Jeon HG; Yang J; Kim SM; Kim TD; Lee E; Kim Y; Choi JS Adv Healthc Mater; 2024 Jun; 13(14):e2303857. PubMed ID: 38344923 [TBL] [Abstract][Full Text] [Related]
16. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821 [TBL] [Abstract][Full Text] [Related]
17. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR Elife; 2021 Oct; 10():. PubMed ID: 34636722 [TBL] [Abstract][Full Text] [Related]
18. The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2. Huang H; Zhang C; Yang S; Xiao W; Zheng Q; Song X J Control Release; 2021 Jul; 335():449-456. PubMed ID: 34029632 [TBL] [Abstract][Full Text] [Related]